Sarcoma Clinical Trials in Boston, Massachusetts
9 studies are recruiting for sarcoma in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Locations
- 7 in total
- Run by
- Daiichi Sankyo
-
Serial MRI Scans During Radiation Therapy
This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (standard of care cancer treatment) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulv…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Brigham and Women Hospital, Boston, Massachusetts
- Locations
- 2 in total
- Run by
- Dana-Farber Cancer Institute
-
Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention
This study will evaluate strategies to improve physical function and promote exercise and physical activity in adolescents and young adults (AYAs) with sarcoma. The study will assess the feasibility of a standardized triage system for referring AYAs with sarcoma to appropriate exercise and rehabili…
- Stage
- Not phased
- Ages
- 15 to 39
- Site
- Boston Children's Hospital, Boston, Massachusetts
- Locations
- 3 in total
- Run by
- Dana-Farber Cancer Institute
-
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 [PD-1]) in advanced unresectable or metastatic tumors. The Phase 2…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Dana Farber Cancer Institute, Boston, Massachusetts
- Locations
- 10 in total
- Run by
- STORM Therapeutics LTD
-
Distance-Based Exercise to Preserve Function and Prevent Disability
This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side e…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Locations
- 18 in total
- Run by
- Alliance for Clinical Trials in Oncology
-
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers. The study will collect biospecimens and clinical in…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Run by
- Dana-Farber Cancer Institute
-
Video Education With Result Dependent dIsclosure
The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better s…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Dana Farber Cancer Institute, Boston, Massachusetts
- Run by
- Dana-Farber Cancer Institute
-
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
This research is being done to test a new drug called PEEL-224 in combination with two commercially available drugs, Vincristine and Temozolomide, and to determine how effective this combination of drugs is at treating Ewing Sarcoma (EWS) and Desmoplastic Small Round Cell Tumor (DSRCT), as well as …
- Stage
- Phase 1
- Ages
- 12 to 49
- Site
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Locations
- 3 in total
- Run by
- David S Shulman, MD
-
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Massachusetts General Hospital, Boston, Massachusetts
- Locations
- 9 in total
- Run by
- ImmVira Pharma Co. Ltd
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.